Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBP-2205
- Development stage
- Unknown
- Lead developer
- Keythera Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KBP-2205 is an orally administered small molecule drug developed for the treatment of advanced malignant solid neoplasms. It was initially developed by Kaifu (Suzhou) Biomedicine and is also associated with Keythera (Suzhou) Biopharmaceuticals. The drug has completed preclinical candidate validation and entered clinical development, with its highest global R&D status reported as Phase 1. While specific molecular targets or mechanisms of action have not been disclosed in public sources, it is positioned as an anti-cancer agent within the therapeutic area of neoplasms, particularly targeting digestive system cancers[1][3][4][5].
Beyond the preview
Go deeper on KBP-2205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBP-2205.